Survival and prognostic factors in patients with small bowel carcinoid tumour

British Journal of Surgery

Volumn 98, Issue 11, 2011, Pages 1617-1624

  Landerholm, K ^a   Zar, N ^a   Andersson, R E ^a   Falkmer, S E ^a   Jarhult J ^a  

^a RYHOV COUNTY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CANCER INVASION; CARCINOID; CAUSE OF DEATH; DISEASE FREE SURVIVAL; FEMALE; HUMAN; ILEUM TUMOR; JEJUNUM TUMOR; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MORTALITY; PROGNOSIS; REOPERATION; TUMOR RECURRENCE;

AGED; CARCINOID TUMOR; CAUSE OF DEATH; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; ILEAL NEOPLASMS; JEJUNAL NEOPLASMS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PROGNOSIS; REOPERATION;

EID: 80053561728     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.7649     Document Type: Article

References (23)

1. Modlin IM, Champaneria MC, Chan AK, Kidd M,. A three-decade analysis of 3911 small intestinal neuroendocrine tumors: the rapid pace of no progress. Am J Gastroenterol 2007; 102: 1464-1473. (Pubitemid 46976277)
2. Landerholm K, Falkmer S, Järhult J,. Epidemiology of small bowel carcinoids in a defined population. World J Surg 2010; 34: 1500-1505.
3. Onaitis MW, Kirshbom PM, Hayward TZ, Quayle FJ, Feldman JM, Seigler HF, et al., Gastrointestinal carcinoids: characterization by site of origin and hormone production. Ann Surg 2000; 232: 549-556.
4. Perez EA, Koniaris LG, Snell SE, Gutierrez JC, Sumner WE III, Lee DJ, et al., 7201 carcinoids: increasing incidence overall and disproportionate mortality in the elderly. World J Surg 2007; 31: 1022-1030. (Pubitemid 46716758)
5. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al., One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35 825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.
6. Godwin JD II,. Carcinoid tumors. An analysis of 2837 cases. Cancer 1975; 36: 560-569.
7. Lepage C, Rachet B, Coleman MP,. Survival from malignant digestive endocrine tumors in England and Wales: a population-based study. Gastroenterology 2007; 132: 899-904. (Pubitemid 46440869)
8. Zar N, Garmo H, Holmberg L, Rastad J, Hellman P,. Long-term survival of patients with small intestinal carcinoid tumors. World J Surg 2004; 28: 1163-1168. (Pubitemid 40109870)
9. Maggard MA, O'Connell JB, Ko CY,. Updated population-based review of carcinoid tumors. Ann Surg 2004; 240: 117-122. (Pubitemid 38808243)
10. Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS,. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg 2009; 249: 63-71.
11. Bergestuen DS, Aabakken L, Holm K, Vatn M, Thiis-Evensen E,. Small intestinal neuroendocrine tumors: prognostic factors and survival. Scand J Gastroenterol 2009; 44: 1084-1091.
12. Jann H, Roll S, Couvelard A, Hentic O, Pavel M, Müller-Nordhorn J, et al., Neuroendocrine tumors of midgut and hindgut origin: tumor-node- metastasis classification determines clinical outcome. Cancer 2011; 117: 3332-3341.
13. Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM, et al., TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007; 451: 757-762. (Pubitemid 47497934)
14. Sobin LH, Gospodarowicz MK, Wittekind C, (eds). UICC International Union Against Cancer-TNM Classification of Malignant Tumours (7th edn). Wiley-Blackwell: Chichester, 2009.
15. Rindi G, Arnold R, Bosman FT, Capella C, Klimstra DS, Klöppel G, et al., Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In WHO Classification of Tumours of the Digestive System (4th edn), Bosman FT, Carneiro F, Hruban RH, Theise ND, (eds). IARC: Lyon, 2010.
16. Wittekind C, Compton CC, Greene FL, Sobin LH,. TNM residual tumor classification revisited. Cancer 2002; 94: 2511-2516. (Pubitemid 34457134)
17. Dickman PW, Sloggett A, Hills M, Hakulinen T,. Regression models for relative survival. Stat Med 2004; 23: 51-64. (Pubitemid 38072106)
18. Welch HG, Black WC,. Are deaths within 1 month of cancer-directed surgery attributed to cancer? J Natl Cancer Inst 2002; 94: 1066-1070. (Pubitemid 34830726)
19. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al.,; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-4663.
20. Kölby L, Persson G, Franzén S, Ahrén B,. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 2003; 90: 687-693. (Pubitemid 36760596)
21. Arnold R, Rinke A, Klose KJ, Müller HH, Wied M, Zamzow K, et al., Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005; 3: 761-771. (Pubitemid 41116728)
22. Modlin IM, Kidd M, Drozdov I, Siddique Z-L, Gustafsson BI,. Pharmacotherapy of neuroendocrine cancers. Expert Opin Pharmacother 2008; 9: 2617-2626.
23. Hellman P, Lundström T, Ohrvall U, Eriksson B, Skogseid B, Oberg K, et al., Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg 2002; 26: 991-997. (Pubitemid 36920298)